NCT07895017Not yet recruitingPhase 2
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to study how avatrombopag (the study drug) may prevent certain side effects in adults with lymphoma and myeloma getting cancer treatment (CAR-T cell therapy). CAR (Chimeric Antigen Receptor) -T cell therapy is a common way to treat lymphoma and myeloma. However, during this kind of cell therapy a patient is at risk of developing lower-than-normal blood cell counts, including: * Red Blood Cells - important for many functions such as moving oxygen from the lungs to the body and moving carbon dioxide (CO2) back to the lungs * White Blood Cells - help fight against infection(s) * Platelets - help stop bleeding by forming clots when there is an injury When a person's platelet counts are lower than normal, this is called "thrombocytopenia". If you have thrombocytopenia, your body has a harder time stopping a bleed when there is an injury to a blood vessel. Thrombocytopenia over time may require additional treatments such as blood transfusions (getting extra platelets). Avatrombopag is a drug that has been shown to increase platelet numbers in people with other kinds of conditions. This study is trying to find out if taking avatrombopag both before and after CAR-T cell therapy will prevent platelet counts from getting too low. This is a research study to see if taking avatrombopag (in the form of pills) before, during, and after CAR-T cell therapy will reduce the chance of having thrombocytopenia as a side effect. This study is for people who are at high risk of thrombocytopenia after CAR T-Cell Therapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 14 Sept 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 31 Aug 2029
- Lead sponsor
- University of Virginia
- Diseases
- Multiple myeloma
- NCT number
- NCT07895017
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 26
- From 1 Nov 2026 to the primary completion date, 31 Aug 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with another investigational drug within 3 weeks prior to registration.
Other illness
- Known allergic reactions to components of the avatrombopag, specifically subjects with anaphylaxis, bleeding, or other severe adverse reactions related to avatrombopag or its components
- Subjects with acute arterial or venous thromboembolism within the past 6 months
- Subjects with a history of MDS or AML
Lab values
- Subjects who are at increased risk for thromboembolism, including patients with platelets \> 400k/ul, previously known genetic prothrombotic conditions (e.g., Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S deficiency) and acquired risk factors (e.g., antiphospholipid syndrome).
Other
- Pregnancy (urine or blood beta-hcg) or lactation
Who the study is looking for
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged ≥ 18 years old
- ECOG performance status ≤ 2
- Planned to receive FDA approved CAR T-cell therapy for large B-cell lymphoma, follicular lymphoma, mantle-cell lymphoma, chronic lymphocytic lymphoma, or multiple myeloma including (but not limited to): idecabtagene vicleucel, lisocabtagene maraleucel, ciltacabtagene autoleucel, tisagenlecleucel, brexucabtagene autoleucel, or axicabtagene ciloleucel
- At least one of the following:
- Platelet count \<200K
- High CAR-HEMATOTOX score
- Organ Function per the following criteria:
- Plt - \>20K CrCl - \>30 ml/min, (expectation for participants with chronic kidney disease presenting with CrCl \<30 but within 15% of baseline) Bilirubin - \<3.0 (unless diagnosed with Gilbert's, can be to PI discretion) AST and ALT - ≤ 3 x ULN
- Ability to take oral medication and be willing to adhere to the avatrombopag regimen
- Agreement to adhere to Lifestyle Considerations throughout study duration
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Virginia Coordinator of this site? Confirm its status | Charlottesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.